Novo Nordisk announced a strategic partnership with OpenAI to integrate AI across its entire business.
Scope
The partnership covers: drug discovery and target identification, clinical trial design, manufacturing optimization for biologics, supply chain management, and commercial operations.
Target focus
The primary aim is accelerating identification of new treatments for obesity and diabetes — Novo Nordisk's core therapeutic areas. AI-assisted compound screening could compress early-stage discovery timelines from years to months.
Industry context
Part of a broader wave of pharma AI deals: Eli Lilly, Pfizer, and Roche have signed similar agreements with major AI labs in the past 18 months.